Anika Therapeutics price to free cash flow ANIK
Market value divided by free cash flow over the last twelve months, since 2012.
- Today, Nov 2, 2026
- 462×
- 10-year median
- 32.0×
- Against its 10-year history
- 98th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 10.7× to 499×
- Peer median
- 12.2×
Anika Therapeutics' price to free cash flow is 462× as of Nov 2, 2026.
That is above its ten-year median of 32.0×, higher than on 98% of days in the last ten years.
Over that time it ranged from 10.7× in Mar 2020 to 499× in Oct 2026.
The median for 10 medical instruments and supplies stocks of a similar size is 12.2×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 462× | 42.5× | 499× |
| 2025 | 213× | 213× | 222× |
| 2024 | 215× | 215× | 335× |
| 2023 | 165× | 165× | 202× |
| 2022 | 187× | 95.7× | 242× |
| 2021 | 253× | 22.3× | 318× |
| 2020 | 29.2× | 10.7× | 29.2× |
| 2019 | 24.1× | 13.8× | 32.3× |
| 2018 | 18.2× | 17.2× | 31.3× |
| 2017 | 24.9× | 24.1× | 69.1× |
| 2016 | 53.3× | 15.0× | 57.2× |
| 2015 | 15.6× | 13.2× | 19.9× |
| 2014 | 17.6× | 14.8× | 27.1× |
| 2013 | 23.6× | 11.5× | 25.0× |
| 2012 | 11.7× | 11.7× | 36.7× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| ANIKAnika Therapeutics | 462× |
| INFUInfuSystem | 12.0× |
| UTMDUtah Medical Products | 19.6× |
| EMBCEmbecta | 2.1× |
| PDEXPro DEX | 17.3× |
| TCMDTactile Systems Technology | 19.3× |
| KEQUKewaunee Scientific | 8.9× |
| MOVMovado | 10.0× |
| IRMDIradimed | 38.9× |
| IARTIntegra Lifesciences | 12.3× |
| BVSBioventus | 11.7× |
| Peer median | 12.2× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Anika Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.